

PRESS RELEASE

Hansa Biopharma to host conference call to provide interim results for January-March 2022 and Business Update

Lund, Sweden April 8, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2022 at 8:00 CET on April 21, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 20 3936 2999

United States: +1 646 664 1960

The webcast will be available on <https://streams.eventcdn.net/hansa/q1-2022/>

Updated Calendar and Events 2022

| | |
|-----------------------|---|
| April 13, 2022 | Needham Healthcare Conference 2022 |
| April 21, 2022 | Interim Report for January-March 2022 |
| April 21, 2022 | Kempen Life Sciences Conference 2022, Amsterdam |
| April 27, 2022 | Redeye Orphan Drugs 2022, Stockholm |
| May 15, 2022 | ABG Life Science Summit, Stockholm |
| May 16, 2022 | European Midcap Event, Copenhagen |
| June 16, 2022 | Annual General Meeting 2022 |
| July 12, 2022 | William Blair's Biotech Focus Conference 2022, New York |
| July 21, 2022 | Half year 2022 report |
| Aug 9, 2022 | BTIG Biotechnology Conference 2022, New York |
| Aug 10, 2022 | Canaccord Annual Growth Conference, Boston |
| Sept 7-8, 2022 | Pareto annual healthcare conference, Stockholm |
| Sept 7-8, 2022 | Citi's 17th Annual BioPharma Conference, Boston |
| Oct 20, 2022 | Interim Report for January-September 2022 |
| Nov 23, 2022 | Økonomisk Ugebrev Life Science konference, Copenhagen |

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

Katja Margell, *Head of Corporate Communications*

M: +46 (0) 768-198 326

E: katja.margell@hansabiopharma.com